Shanghai Serum Bio-Technology Co. Ltd. A
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co. Ltd. A (688163) - Total Assets
Latest total assets as of June 2025: CN¥1.14 Billion CNY
Based on the latest financial reports, Shanghai Serum Bio-Technology Co. Ltd. A (688163) holds total assets worth CN¥1.14 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Serum Bio-Technology Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Shanghai Serum Bio-Technology Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Serum Bio-Technology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Serum Bio-Technology Co. Ltd. A's total assets of CN¥1.14 Billion consist of 81.8% current assets and 18.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.3% |
| Accounts Receivable | CN¥36.68 Million | 3.3% |
| Inventory | CN¥43.28 Million | 3.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥23.03 Million | 2.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Shanghai Serum Bio-Technology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Serum Bio-Technology Co. Ltd. A's current assets represent 81.8% of total assets in 2024, an increase from 63.3% in 2019.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2024, down from 36.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 3.9% of total assets.
Shanghai Serum Bio-Technology Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai Serum Bio-Technology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shanghai Serum Bio-Technology Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai Serum Bio-Technology Co. Ltd. A generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shanghai Serum Bio-Technology Co. Ltd. A generates $ 3.95 in net profit.
Shanghai Serum Bio-Technology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 37.85 | 52.15 | 77.53 |
| Quick Ratio | 36.09 | 49.77 | 73.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥883.92 Million | CN¥ 920.26 Million | CN¥ 1.02 Billion |
Shanghai Serum Bio-Technology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai Serum Bio-Technology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | CN¥1.12 Billion |
| Market Capitalization | $144.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Serum Bio-Technology Co. Ltd. A's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shanghai Serum Bio-Technology Co. Ltd. A's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shanghai Serum Bio-Technology Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Shanghai Serum Bio-Technology Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.12 Billion | -0.75% |
| 2023-12-31 | CN¥1.13 Billion | -3.26% |
| 2022-12-31 | CN¥1.17 Billion | +189.53% |
| 2021-12-31 | CN¥402.89 Million | +23.48% |
| 2020-12-31 | CN¥326.29 Million | -10.63% |
| 2019-12-31 | CN¥365.11 Million | -- |